clinical trial · NCT07510945
HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective Surgery
Haisco Pharmaceutical Group Co., Ltd.·phase3·not yet recruiting·n = 400
General AnestheticHSK3486propofol
brief summary
This multicenter, randomized, double-blinded, propofol-controlled Phase 3b study enrolls pediatric subjects aged 3-17 years undergoing elective surgery with endotracheal intubation. Its primary purpose is to evaluate whether cipepofol is non-inferior to propofol in success of induction of general anesthesia in pediatrics undergoing elective surgery.
started
May 1, 2026
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Apr 6, 2026
official title
A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3b Clinical Study to Evaluate the Efficacy and Safety of HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol